Status:
UNKNOWN
Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin®/Zeribev®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
COVID19 Pneumonia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Bevacizumab, ZERIBEV® (Pfizer)/AVASTIN® (Roche) 25 mg/ml ®, is a recombinant humanised monoclonal IgG1 antibody It seems interesting to use bevacizumab in severe patients infected with SARS-CoV-2 requ...
Eligibility Criteria
Inclusion
- Patients Requiring more than 3L/min of oxygen
- WHO progression scale = 5 to 8
Exclusion
- Patients in 9 WHO progression class
- Patients with exclusion criteria to the CORIMUNO-19 cohort.
- Hypersensitivity to Bevacizumab or to any of their excipients.
- Pregnancy
- Active Cancer with undergoing treatment
- Oxygen patient requiring long-term oxygen before hospitalization
- Patient already included in a therapeutic trial; however, inclusion should be discussed case by case with the trial coordinator.
- Contraindication to bevacizumab, risk of bleeding especially hemoptysis, active venous or arterial thromboembolic disease and recent surgery.
- Hypersensitivity to the active substance or one of the excipients
Key Trial Info
Start Date :
April 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 30 2020
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT04344782
Start Date
April 15 2020
End Date
November 30 2020
Last Update
April 17 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.